FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901961906> ?p ?o ?g. }

• W2901961906 endingPage "116" @default.
• W2901961906 startingPage "107" @default.
• W2901961906 abstract "Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme Chase Burton,1,* Arabinda Das,2,* Daniel McDonald,3 William A Vandergrift III,2 Sunil J Patel,2 David Cachia,2 Eric Bartee1 1Department of Microbiology and Immunology, Medical University of South Carolina, SC, USA; 2Department of Neurosurgery, Medical University of South Carolina, SC, USA; 3Department of Radiation Oncology, Medical University of South Carolina, SC, USA *These authors contributed equally to this work Background: Glioblastoma multiforme (GBM) is an aggressive form of brain cancer which is associated with poor prognosis. A variety of oncolytic viruses have previously shown positive efficacy against GBM, potentially offering new treatment options for patients. One such oncolytic virus is Myxoma virus (MYXV), a rabbit-specific poxvirus that has been shown to be efficacious against a variety of tumor models including GBM. Purpose: The purpose of this study was to test the efficacy of MYXV combined with current treatment regimens for GBM in both established cell lines as well as patient biopsy samples. Materials and methods: U118 gliobastoma cell lines were treated under various standard of care combinations (untreated, radiation and chemotherapeutic) prior to infection with MYXV. Infection was then monitored for differences in rate of infection, titer and rate of spread. Cellular death was measured by MTT assay and Caspase-3 colorimetric assay. Patient biopsies were harvested and treated under similar treatment conditions. Results: The addition of GBM standard of care to MYXV infection resulted in an increased rate of spread compared to single treatment with either radiation or chemotherapeutic alone. SOC did not alter viral replication or infection rates. Similar effects were seen in ex vivo patient biopsies. Cellular viability was significantly decreased with the combination therapy of SOC and MYXV infection compared to any other treatment outcome. Caspase-3 activity was also significantly increased in samples treated with combination therapy when compared to any other treatment combination. Conclusion: Our results show that the combination of MYXV with current SOC results in both increased killing of GBM cells compared to either treatment regime alone as well as increased spread of MYXV infection. These findings lay the foundation for future in vivo studies on combining MYXV with GBM SOC. Keywords: myxoma virus, glioblastoma multiforme, standard of care, oncolytic virotherapy" @default.
• W2901961906 created "2018-11-29" @default.
• W2901961906 creator A5036099450 @default.
• W2901961906 creator A5047382443 @default.
• W2901961906 creator A5056374928 @default.
• W2901961906 creator A5064633354 @default.
• W2901961906 creator A5071400951 @default.
• W2901961906 creator A5075325366 @default.
• W2901961906 creator A5080840460 @default.
• W2901961906 date "2018-11-01" @default.
• W2901961906 modified "2023-10-05" @default.
• W2901961906 title "Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiforme" @default.
• W2901961906 cites W1581070393 @default.
• W2901961906 cites W162807232 @default.
• W2901961906 cites W1924902828 @default.
• W2901961906 cites W1988962933 @default.
• W2901961906 cites W2023171244 @default.
• W2901961906 cites W2027219473 @default.
• W2901961906 cites W2069272353 @default.
• W2901961906 cites W2073421271 @default.
• W2901961906 cites W2074111828 @default.
• W2901961906 cites W2077363280 @default.
• W2901961906 cites W2080167568 @default.
• W2901961906 cites W2089157311 @default.
• W2901961906 cites W2096287682 @default.
• W2901961906 cites W2113942802 @default.
• W2901961906 cites W2115459972 @default.
• W2901961906 cites W2120820093 @default.
• W2901961906 cites W2125940163 @default.
• W2901961906 cites W2134045444 @default.
• W2901961906 cites W2134807618 @default.
• W2901961906 cites W2148977460 @default.
• W2901961906 cites W2156941745 @default.
• W2901961906 cites W2159485898 @default.
• W2901961906 cites W2165114272 @default.
• W2901961906 cites W2165839182 @default.
• W2901961906 cites W2203548798 @default.
• W2901961906 cites W2405488873 @default.
• W2901961906 cites W2505666614 @default.
• W2901961906 cites W2559830231 @default.
• W2901961906 cites W2561281811 @default.
• W2901961906 cites W2596479132 @default.
• W2901961906 cites W2783130730 @default.
• W2901961906 cites W2792118664 @default.
• W2901961906 cites W2912795122 @default.
• W2901961906 cites W4242403727 @default.
• W2901961906 cites W760546722 @default.
• W2901961906 doi "https://doi.org/10.2147/ov.s179335" @default.
• W2901961906 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6251439" @default.
• W2901961906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30538967" @default.
• W2901961906 hasPublicationYear "2018" @default.
• W2901961906 type Work @default.
• W2901961906 sameAs 2901961906 @default.
• W2901961906 citedByCount "13" @default.
• W2901961906 countsByYear W29019619062019 @default.
• W2901961906 countsByYear W29019619062020 @default.
• W2901961906 countsByYear W29019619062021 @default.
• W2901961906 countsByYear W29019619062022 @default.
• W2901961906 countsByYear W29019619062023 @default.
• W2901961906 crossrefType "journal-article" @default.
• W2901961906 hasAuthorship W2901961906A5036099450 @default.
• W2901961906 hasAuthorship W2901961906A5047382443 @default.
• W2901961906 hasAuthorship W2901961906A5056374928 @default.
• W2901961906 hasAuthorship W2901961906A5064633354 @default.
• W2901961906 hasAuthorship W2901961906A5071400951 @default.
• W2901961906 hasAuthorship W2901961906A5075325366 @default.
• W2901961906 hasAuthorship W2901961906A5080840460 @default.
• W2901961906 hasBestOaLocation W29019619061 @default.
• W2901961906 hasConcept C121608353 @default.
• W2901961906 hasConcept C126322002 @default.
• W2901961906 hasConcept C143998085 @default.
• W2901961906 hasConcept C159047783 @default.
• W2901961906 hasConcept C2522874641 @default.
• W2901961906 hasConcept C2776194525 @default.
• W2901961906 hasConcept C2779745803 @default.
• W2901961906 hasConcept C502942594 @default.
• W2901961906 hasConcept C509974204 @default.
• W2901961906 hasConcept C71924100 @default.
• W2901961906 hasConcept C82210918 @default.
• W2901961906 hasConceptScore W2901961906C121608353 @default.
• W2901961906 hasConceptScore W2901961906C126322002 @default.
• W2901961906 hasConceptScore W2901961906C143998085 @default.
• W2901961906 hasConceptScore W2901961906C159047783 @default.
• W2901961906 hasConceptScore W2901961906C2522874641 @default.
• W2901961906 hasConceptScore W2901961906C2776194525 @default.
• W2901961906 hasConceptScore W2901961906C2779745803 @default.
• W2901961906 hasConceptScore W2901961906C502942594 @default.
• W2901961906 hasConceptScore W2901961906C509974204 @default.
• W2901961906 hasConceptScore W2901961906C71924100 @default.
• W2901961906 hasConceptScore W2901961906C82210918 @default.
• W2901961906 hasLocation W29019619061 @default.
• W2901961906 hasLocation W29019619062 @default.
• W2901961906 hasLocation W29019619063 @default.
• W2901961906 hasLocation W29019619064 @default.
• W2901961906 hasOpenAccess W2901961906 @default.
• W2901961906 hasPrimaryLocation W29019619061 @default.
• W2901961906 hasRelatedWork W1993591401 @default.
• W2901961906 hasRelatedWork W2031066088 @default.

• next